PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Jun 2, 2017
SOUTH PLAINFIELD, N.J., June 2, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 30, 2017 it approved non-statutory stock options to purchase an aggregate of 46,000 shares of its common stock to seven new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new...
May 23, 2017
SOUTH PLAINFIELD, N.J., May 23, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of new post-hoc analyses from the placebo arm of its ACT DMD Phase 3 trial with respect to the effect of corticosteroids on multiple measures of disease progression. Siva Narayanan, Vice President and Global Head, Market Acces...
May 19, 2017
SOUTH PLAINFIELD, N.J., May 19, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 17, 2017 it approved non-statutory stock options to purchase 46,500 shares of its common stock to ten new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment...
May 8, 2017
SOUTH PLAINFIELD, N.J., May 8, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2017. "We are thrilled to bring EMFLAZA to Duchenne muscular dystrophy patients in the United States," said Stuart W. Peltz, Ph.D., Chief Executive...
Apr 26, 2017
SOUTH PLAINFIELD, N.J., April 26, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 21, 2017 it approved non-statutory stock options to purchase 266,400 shares of its common stock to 32 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employ...
Apr 24, 2017
SOUTH PLAINFIELD, N.J., April 24, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter financial results and provide an update on the company's business and outlook on Monday, May 8, 2017 at 8:30 a.m. (ET) before the opening of the market. ...
Apr 20, 2017
SOUTH PLAINFIELD, N.J., April 20, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has completed its acquisition of all rights to Emflaza™ (deflazacort) for the treatment of Duchenne muscular dystrophy (DMD) in the U.S. Execution of the asset purchase agreement setting forth the terms of the acquisition was announ...
Apr 10, 2017
SOUTH PLAINFIELD, N.J., April 10, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Shane Kovacs, Chief Financial Officer, will be leaving the company in mid-May 2017 to return to the finance sector, joining RBC Capital Markets as Managing Director where he will help lead the firm's biotech investment banking efforts. ...
Mar 16, 2017
SOUTH PLAINFIELD, N.J., March 16, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2016. "For nearly 20 years, PTC has been committed to delivering new treatment options to patients living with Duchenne muscul...
Mar 16, 2017
SOUTH PLAINFIELD, N.J., March 16, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has entered into an asset purchase agreement with Marathon Pharmaceuticals, LLC to acquire all rights to Emflaza™ (deflazacort). Emflaza is the first treatment approved in the United States for all Duchenne muscular dystrophy (DMD) ...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue